In the final Phase III clinical trial, the new active substance olokizumab has demonstrated that it is at least as effective as the current gold standard in the treatment of rheumatoid arthritis. This standard consists of a combination of the active substances adalimumab (a tumour necrosis factor (TNF) inhibitor) and methotrexate (a folic acid antagonist) and is used in patients for whom initial treatment with methotrexate is not sufficiently effective. Despite this and other effective medicines, up to 25 per cent of treated patients do not respond to any of the current treatment options.
Olokizumab is a humanised monoclonal antibody that targets the cytokine interleukin-6 directly. This is a messenger substance that regulates the body’s inflammatory responses and is involved in the progression of rheumatoid arthritis. Olokizumab is the first direct inhibitor of interleukin-6 to be on the verge of approval for commercial use in this indication.
In the Phase III clinical trial involving over 1,600 participants, the new active substance was investigated for its efficacy in combination with methotrexate. The result: it proved to be at least as effective as the current gold standard. “The new active substance ensures that many patients achieve low disease activity, the primary treatment goal; in one in eight cases, there is even a complete remission of active disease symptoms,” explains study leader Josef Smolen from the Clinical Department of Rheumatology at the University Clinic for Internal Medicine III at MedUni Vienna and Vienna General Hospital (AKH). “At the same time, this significantly broadens the existing range of treatments, as this active substance works differently from conventional medicines.” “This will provide
us with another excellent treatment option in future,” explains Daniel Aletaha, Head of the Clinical Department of Rheumatology. “We now have another option for patients who respond little or not at all to established treatments.” The new drug is due to be submitted for approval in the EU and the US. The researchers expect it to enter clinical use in the course of the coming year.
The results of the international multicentre study led by MedUni Vienna have recently been published in the prestigious New England Journal of Medicine.
Reference:
Medical University of Vienna
, Smolen J et al., Olokizumab versus placebo or adalimumab in rheumatoid arthritis;
N Engl J Med 2022;387:715–26. DOI: 10.1056/NEJMoa2201302
#rheumatoidarthritis #rheumatism #olokizumab #methotrexate #medicine #science